Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
Condition: PCNSL Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Methotrexate; Drug: Temozolomide Sponsor: Ruijin Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chemotherapy | Hospitals | Methotrexate | Primary CNS Lymphoma | Research | Rituxan | Temodar